Gut microbial carbohydrate metabolism contributes to insulin resistance.
Takeuchi T, Kubota T, Nakanishi Y, Tsugawa H, Suda W, Kwon AT, Yazaki J, Ikeda K, Nemoto S, Mochizuki Y, Kitami T, Yugi K, Mizuno Y, Yamamichi N, Yamazaki T, Takamoto I, Kubota N, Kadowaki T, Arner E, Carninci P, Ohara O, Arita M, Hattori M, Koyasu S, Ohno H. · 2023
Read Gut microbial carbohydrate metabolism contributes to insulin resistance. by Takeuchi T, Kubota T, Nakanishi Y, Tsugawa H, Suda W, Kwon AT, Yazaki J, Ikeda K, Nemoto S, Mochizuki Y, Kitami T, Yugi K, Mizuno Y, Yamamichi N, Yamazaki T, Takamoto I, Kubota N, Kadowaki T, Arner E, Carninci P, Ohara O, Arita M, Hattori M, Koyasu S, Ohno H. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10499599.txt.
Introduction
Takeuchi and a large team linked gut microbe sugar use to insulin resistance in 2023. Insulin resistance is the core fault behind metabolic syndrome and type 2 diabetes. In it, body cells respond weakly to insulin, the hormone that lowers blood sugar. Gut microbes help digest food, and their sugar use may feed the fault.
The team joined stool chemistry, microbe gene reads, and blood data in humans. Stools of resistant people held more simple sugars that the body can absorb. Takeuchi tied that surplus to microbe sugar paths and to swelling signals. Some gut bacteria tracked with resistance, others with healthy response. The healthy-response set eased the fault when fed to mice.
Catalog record
| CREATOR | Takeuchi T, Kubota T, Nakanishi Y, Tsugawa H, Suda W, Kwon AT, Yazaki J, Ikeda K, Nemoto S, Mochizuki Y, Kitami T, Yugi K, Mizuno Y, Yamamichi N, Yamazaki T, Takamoto I, Kubota N, Kadowaki T, Arner E, Carninci P, Ohara O, Arita M, Hattori M, Koyasu S, Ohno H. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 119 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Gut microbial carbohydrate metabolism contributes to insulin resistance By Tadashi Takeuchi, Tetsuya Kubota, Yumiko Nakanishi, Hiroshi Tsugawa, Wataru Suda, Andrew Tae-Jun Kwon, Junshi Yazaki, Kazutaka Ikeda, Shino Nemoto, Yoshiki Mochizuki, Toshimori Kitami, Katsuyuki Yugi Published in: Nature DOI: 10.1038/s41586-023-06466-x ABSTRACT Abstract Insulin resistance is the primary pathophysiology underlying metabolic syndrome and type 2 diabetes1,2. Previous metagenomic studies have described the characteristics of gut microbiota and their roles in metabolizing major nutrients in insulin resistance3–9. In particular, carbohydrate metabolism of commensals has been proposed to contribute up to 10% of the host’s overall energy extraction10, thereby playing a role in the pathogenesis of obesity and prediabetes3,4,6. Nevertheless, the underlying mechanism remains unclear. Here we investigate this relationship using a comprehensive multi-omics strategy in humans. We combine unbiased faecal metabolomics with metagenomics, host metabolomics and transcriptomics data to profile the involvement of the microbiome in insulin resistance. These data reveal that faecal carbohydrates, particularly host-accessible monosaccharides, are increased in individuals with insulin resistance and are associated with microbial carbohydrate metabolisms and host inflammatory cytokines. We identify gut bacteria associated with insulin resistance and insulin sensitivity that show a distinct pattern of carbohydrate metabolism, and demonstrate that insulin-sensitivity-associated bacteria ameliorate host phenotypes of insulin resistance in a mouse model. Our study, which provides a comprehensive view of the host–microorganism relationships in insulin resistance, reveals the impact of carbohydrate metabolism by microbiota, suggesting a potential therapeutic target for ameliorating insulin resistance. Subject terms: Metabolomics, Next-generation sequencing, Pre-diabetes, Microbiome, Metagenomics MAIN We analysed 306 individuals (71% male) aged from 20 to 75 years (median age, 61 years), who were recruited during their annual health check-ups (Extended Data Fig. 1a). Individuals diagnosed with diabetes were excluded to avoid any long-lasting effects of hyperglycaemia5,6. Consequently, our study included relatively healthy individuals compared with most of the previous metagenomic studies of diabetes and obesity5–8,11,12; the median (interquartile range (IQR)) body mass index (BMI) and glycated haemoglobin (HbA1c) were 24.9 kg m−2 (22.2–27.1 kg m−2) and 5.8% (5.5–6.1%), respectively (Supplementary Table 1). The main clinical phenotype analysed in this study was insulin resistance (IR), which we defined as a homeostatic model assessment of IR (HOMA-IR) score of at least 2.5 (ref. 13). We also analysed the associations between faecal metabolites and metabolic syndrome (MetS), an IR-related pathology. The clinical characteristics of IR and MetS largely overlapped except for blood pressure and sex ratio, for which there was no difference between individuals with IR versus normal insulin sensitivity (IS) (Supplementary Table 1). Untargeted metabolomics analysis using two mass spectrometry (MS)-based analytical platforms identified 195 and 100 annotated faecal and plasma hydrophilic metabolites, and 2,654 and 635 annotated faecal and plasma lipid metabolites, respectively (Extended Data Fig. 1a). To identify the overall difference in microbial functions, faecal metabolites and predicted genes were summarized into co-abundance groups (CAGs) and KEGG categories, respectively (Extended Data Fig. 1b). Transcriptomic information of peripheral blood mononuclear cells (PBMCs) was obtained using the cap analysis of gene expression (CAGE) method14, which can measure gene expression at the transcription-start-site resolution. [Figure: Overview of multi-omics analysis and data.a, Individuals without a prior diagnosis of diabetes, diabetic medications, or intestinal diseases were included (n = 306). Insulin resistance (IR) and metabolic syndrome (MetS) were the main clinical phenotypes. To evaluate the host-microbe relationship, we collected 1) host factors: clinical, plasma metabolome, peripheral blood mononuclear cells (PBMC) transcriptome, and cytokine data, and 2) microbial factors: 16S rRNA pyrosequencing, shotgun metagenome, and faecal metabolome. The numbers of elements after quality filtering are shown for each data set. b, The multi-omics analysis workflow. To identify the microbes that affect metabolic phenotypes, we first analysed the phenotype-associated metabolomic signatures by binning metabolites into co-abundance groups (CAGs). Microbial signatures were determined using the 16S and metagenomic datasets, and their associations with metabolites were analysed. To gain insight into the host-microbe relationship, the associations among faecal metabolites/microbes and host plasma metabolites, cytokines, and PBMC genes were analysed. We also assessed the mediation effects of plasma cytokines on the relationships between faecal metabolites and metabolic markers. Finally, to validate the effects of candidate metabolites/microbes on metabolic phenotypes, we performed bacterial culture and animal experiments. The associations between clinical phenotypes and omics markers were adjusted by age and sex wherever appropriate.] To examine how omics data of faecal samples can predict IR, we first compared the area under the curve (AUC) of receiver operating characteristic (ROC) curves on the basis of random-forest classifiers. Predictor variables for the models were selected using the minimum-redundancy maximum-relevance algorithm15 from the faecal 16S, metabolome, metagenome and their merged datasets (Supplementary Table 2). We found that the selected features of faecal metabolomic data generally outperformed those of 16S and metagenomics in predicting IR (Fig. 1a), suggesting that faecal metabolomics could be used to study IR pathogenesis. [Figure: Faecal carbohydrate metabolites are distinctly altered in IR.a, Left, the AUC of random forest classifiers was used to predict IR based on genus-level 16S (n = 282), metagenome at the KEGG orthologue (KO) level (n = 266), faecal metabolome and metagenome (KEGG orthologue) + faecal metabolome (n = 266) data. The number of featured markers selected from the datasets increases along the x axis. Right, the box plots show the AUC obtained by selected features. Each dot represents an AUC value of a random-forest classifier using a given number of selected features as predictor variables. b, CAGs of faecal hydrophilic metabolites (hydroCAG, top) and lipid metabolites (lipidCAG, bottom), and clinical phenotypes and markers (n = 282). The two-column heat map on the left represents the associations with the main clinical phenotypes (IR and MetS) analysed using rank-based linear regression, whereas the main heat map shows the partial Spearman’s correlations (pSC) adjusted by age and sex with representative metabolic markers. Only the CAGs with adjusted P (Padj) < 0.05 are coloured. The category names for CAGs were determined on the basis of the most abundant metabolites in the CAGs. Further details are provided in Supplementary Tables 3–8. FBG, fasting blood glucose; neg., negative; pos., positive. The lipid abbreviations are defined in Supplementary Table 27. c, pSC between HOMA-IR and faecal levels of monosaccharides. The coefficients (pSC) and Padj values are described (n = 282). d, Faecal levels of monosaccharides in MetS (n = 306). For a, the box plots indicate the median (centre line), upper and lower quartiles (box limits), and upper and lower extremes except for outliers (whiskers). conc., concentration. For c, the density plots indicate median and distribution. For a and d, statistical analysis was performed using Kruskal–Wallis tests followed by Dunn’s test (a) and rank-based linear regression adjusted by age and sex (d); *P < 0.05, **P < 0.01, ***P < 0.001. See the Source Data (a) and Supplementary Table 5 (d) for exact P values.Source Data] FAECAL CARBOHYDRATES ARE INCREASED IN IR We next searched for the associations between clinical phenotypes and faecal metabolite CAGs (Fig. 1b and Supplementary Tables 3–8). Major confounding factors, namely sex and age, were adjusted throughout the correlation and regression analyses with clinical markers. Among the hydrophilic metabolites, most of the CAGs showing significant associations with IR were those of carbohydrate metabolites, mainly monosaccharides (hydrophilic CAGs 5, 12 and 15; Fig. 1b, top). Short-chain fatty acids (SCFAs), which